<a href="https://laohu8.com/S/ELUT">Elutia</a> Inc. reports Q3 net sales of $3.3 million
Elutia Inc. reported third quarter 2025 net sales of $3.3 million, down from $3.7 million in the same period of 2024. Net sales of SimpliDerm were $2.4 million, compared to $3.1 million in the prior year quarter, while net sales of Cardiovascular products rose to $0.9 million from $0.6 million. Gross margin was 55.8%, up from 48.9%. The company reported a net loss from discontinued operations of $3.5 million, compared to a net loss of $2.1 million in the previous year. Adjusted EBITDA was a loss of $2.7 million, similar to the prior year. As of September 30, 2025, cash balance was $4.7 million. On October 1, 2025, Elutia closed the $88 million sale of its BioEnvelope business to Boston Scientific Corporation, receiving $80.3 million, of which $27.8 million was used to pay off its loan facility and $8 million was placed in escrow. The proceeds will help fund the development of NXT-41x.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elutia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-107741), on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.